Perrigo (NYSE:PRGO) Issues Earnings Results

Perrigo (NYSE:PRGO) announced its quarterly earnings data on Wednesday. The company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.51 by $0.09, FiscalAI reports. Perrigo had a negative net margin of 41.85% and a positive return on equity of 11.25%. The business had revenue of $988.60 million during the quarter, compared to analyst estimates of $984.80 million. During the same period last year, the firm posted $0.80 EPS. The company’s revenue was down 5.2% on a year-over-year basis.

Here are the key takeaways from Perrigo’s conference call:

• Sequential operating trends improved: Core sales declined 1.7% year over year, a narrower drop than in the first half, while core adjusted operating margin rose to 14.3% from 13.4% in Q2. Perrigo also gained 30 basis points of U.S. store-brand OTC share and 80 basis points across key European brands.
• Retailer inventory caution and European softness weighed on results and outlook. Management said retailers built less cough-and-cold inventory than expected and European demand remained weak; it lowered its 2026 sales outlook, while noting seasonal replenishment could fall in Q4 or Q1.
• Core adjusted operating margin fell 210 basis points year over year to 14.3%, and core adjusted EPS declined $0.06 to $0.61. Lower sales and unfavorable mix hurt results; a 3.5% adjusted tax rate, including a year-to-date catch-up, added about $0.10 to quarterly core EPS.
• The infant formula divestiture is expected to simplify the business, improve its margin profile, and reduce future capital needs. Perrigo expects to use proceeds in line with its capital priorities, including debt reduction, while continuing its review of oral care; its cost program delivered $42 million of savings year to date.

Perrigo Price Performance

Shares of NYSE:PRGO traded up $0.14 on Wednesday, reaching $15.84. The company’s stock had a trading volume of 4,970,673 shares, compared to its average volume of 2,437,871. Perrigo has a 52-week low of $9.23 and a 52-week high of $17.48. The company has a market cap of $2.20 billion, a P/E ratio of -1.27, a PEG ratio of 1.81 and a beta of 0.71. The company has a 50-day simple moving average of $14.91 and a 200 day simple moving average of $12.49. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.32 and a current ratio of 2.32.

Perrigo Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 15th. Shareholders of record on Friday, November 27th will be given a dividend of $0.29 per share. The ex-dividend date is Friday, November 27th. This represents a $1.16 annualized dividend and a yield of 7.3%. Perrigo’s dividend payout ratio (DPR) is -9.27%.

Wall Street Analyst Weigh In

PRGO has been the subject of several research analyst reports. Zacks Research cut shares of Perrigo from a “hold” rating to a “strong sell” rating in a research note on Thursday, October 29th. Weiss Ratings raised shares of Perrigo from a “sell (d-)” rating to a “sell (d)” rating in a report on Thursday, August 6th. Canaccord Genuity Group raised their price objective on Perrigo from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Finally, Wall Street Zen cut Perrigo from a “buy” rating to a “hold” rating in a report on Saturday. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus price target of $18.50.

Perrigo News Roundup

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Perrigo posted adjusted EPS of $0.60, ahead of the $0.51 consensus estimate. Management also reported sequential operating improvement under its Three-S plan, with market-share gains in U.S. store-brand OTC products and key European brands. Perrigo Q3 2026 results
• Neutral Sentiment: The planned infant formula divestiture is intended to simplify Perrigo’s portfolio and focus investment on higher-return consumer self-care categories. A strategic review of the Oral Care business is still ongoing, leaving the outcome uncertain. Perrigo Q3 2026 results
• Negative Sentiment: Revenue of $988.6 million slightly exceeded estimates but fell 5.2% from a year earlier; adjusted EPS also declined from $0.80 a year ago. Perrigo reported a net loss for the quarter. Its updated 2026 outlook reflects more cautious retailer inventory positioning and continued softness in Europe, which could weigh on results. Perrigo slips to loss in Q3 Perrigo Q3 2026 results

Perrigo Company Profile

Perrigo Company plc is a global consumer self-care company that develops, manufactures and markets over-the-counter health products, wellness products and personal care items. Its portfolio includes products for allergy, pain relief, digestive health, skin care, smoking cessation, women’s health and other everyday health needs, along with vitamins, nutritional supplements and infant nutrition products.

Perrigo supplies products under its own brands, acquired brands and retailer-owned private-label labels.